Paclitaxel for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Nov 2023: Trial started, NCT06199895
  2. 10 Jan 2024: Trial registered, NCT06199895

The trials

NCT06199895: Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

State
Under way
Phase
Phase 2
People
25 planned
Started
28 Nov 2023
Primary completion
Nov 2025
Arms
Paclitaxel Polymeric Micelles for Injection
Results
None posted
  1. 28 Nov 2023: Trial started
  2. 10 Jan 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Abraxane component paclitaxel, Genexol, Onxol, Paxene, Taxol, Yewtaxan, Zisu.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.